Outlook Therapeutics, Inc. (OTLK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 1 | -1 | 2 |
| Operating profit | $m | -67 | -56 | ||||||
| Net profit | $m | -35 | -53 | -66 | -59 | -75 | -62 | -61 | - |
| EPS reported | $ | -1.79 | -1.87 | ||||||
| Operating cashflow per share | $ | -2.03 | -2.24 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -2.03 | -2.24 | ||||||
| Free cash flow | $m | -52 | -57 | ||||||
| Net debt | $m | 22 | -204,137 | ||||||
| Book value equity | $m | -32 | -10 | ||||||
| Book value per share | $ | -1.26 | -0.41 | ||||||
| Number of shares | m | 25.48 | 25.48 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.84 | -2.60 | ||||||
| P/S LTM | x | 19.10 | -23.22 | ||||||
| P/FCF LTM | x | -0.52 | -0.47 | ||||||
| EV/EBITDA LTM | x | -0.77 | -0.79 | ||||||
| EV/Sales LTM | x | 34.75 | -109.86 | ||||||
| Earnings Yield LTM | % | -2.31% | -3.72% | ||||||
| FCF Yield | % | -191.93% | -211.57% | ||||||
| Quality | |||||||||
| ROE | % | +193.94% | +222.01% | ||||||
| ROIC | % | -23.58% | -3.44% | ||||||
| Operating margin | % | -47.44% | +47.83% | ||||||
| Gross margin | % | +46.49% | +1.96% | ||||||
| FCF/Sales | % | -3666.7% | +4911.7% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.72 | -3.10 | ||||||
| Net Debt/EBITDA | x | -0.35 | -0.12 | ||||||
| EBIT/Net interest | x | -236.86 | -210.62 | ||||||
| Net debt/market cap | % | +1.11% | +15.17% | ||||||
| Net debt/Equity | x | -0.68 | 19,642.58 | ||||||
| Gross debt/equity | x | -0.94 | -1.77 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Outlook Therapeutics, Inc. (OTLK)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free